Acid ceramidase upregulation in prostate cancer: Role in tumor development and implications for therapy

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 12, 2009, Pages 1449-1458

  Liu, Xiang ^a   Cheng, Joseph C ^a   Turner, Lorianne S ^a   Elojeimy, Saeed ^a   Beckham, Thomas H ^a   Bielawska, Alicja ^a   Keane, Thomas E ^a   Hannun, Yusuf A ^b   Norris, James S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

acid ceramidase; acid ceramidase inhibition; ceramide; novel target; prostate cancer; therapeutic resistance; tumor progression

Indexed keywords

ACID CERAMIDASE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DAUNORUBICIN; DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; GALACTOSYLCERAMIDE; GEMCITABINE; GLUCOSYLCERAMIDE; LCL 204; LCL 385; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; SPHINGANINE; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; CERAMIDE; SPHINGOLIPID;

CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CANCER TISSUE; CARCINOGENESIS; CHEMOSENSITIVITY; DRUG EFFICACY; ENZYME METABOLISM; HUMAN; IONIZING RADIATION; PHENOTYPE; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR;

ACID CERAMIDASE; ANIMALS; ANTINEOPLASTIC AGENTS; CERAMIDES; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; SPHINGOLIPIDS; UP-REGULATION;

EID: 75349114498     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728220903357512     Document Type: Review

References (100)

1. Zeidan YH, Jenkins RW, Korman JB, et al. Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets 2008;9(8):653-61
2. Angelucci A, Gravina GL, Rucci N, et al. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 2006;13(1):197-210
3. Canil CM, Tannock IF. Is there a role for chemotherapy in prostate cancer? Br J Cancer 2004;91(6):1005-11 (Pubitemid 39336234)
4. Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95(6):751-6 (Pubitemid 40547200)
5. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166(3):876-81 (Pubitemid 32750970)
6. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003;4(4):233-41 (Pubitemid 36503321)
7. Scardino PT. Early detection of prostate cancer. Urol Clin North Am 1989;16(4):635-55 (Pubitemid 19277265)
8. Seidman H, Mushinski MH, Gelb SK, Silverberg E. Probabilities of eventually developing or dying of cancer-United States, 1985. Ca Cancer J Clin 1985;35(1):36-56
9. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4(8):604-16 (Pubitemid 39025055)
10. Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep 2004;5(8):777-82 (Pubitemid 39199166)
11. Kim WJ, Okimoto RA, Purton LE, et al. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood 2008;111(9):4716-22
12. Norris JS, Bielawska A, Day T, et al. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther 2006;13(12):1045-51 (Pubitemid 44760102)
13. Ruckhaberle E, Rody A, Engels K, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008;112(1):41-52
14. Senkal CE, Ponnusamy S, Rossi MJ, et al. Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 2007;6(2):712-22 (Pubitemid 46332472)
15. Tilly JL, Kolesnick RN. Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility. Biochimica et Biophysica Acta (BBA)-Mol Cell Biol Lipids 2002;1585(2-3):135-8 (Pubitemid 36092077)
16. Wang X-Z, Beebe JR, Pwiti L, et al. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res 1999;59(22):5842-8
17. Mahdy AEM, Cheng JC, Li J, et al. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther 2008;17(3):430-8
18. Pchejetski D, Doumerc N, Golzio M, et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 2008;7(7):1836-45
19. Liu Y-Y, Han T-Y, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999;274(2):1140-6
20. Gouaze V, Yu JY, Bleicher RJ, et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 2004;3(5):633-9 (Pubitemid 39193742)
21. van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 2007;67(10):4843-50 (Pubitemid 46910193)
22. Veldman RJ, Klappe K, Hinrichs J, et al. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J 2002;16(9):1111-3
23. Pchejetski D, Golzio M, Bonhoure E, et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 2005;65(24):11667-75 (Pubitemid 41821727)
24. Garzotto M, Haimovitz-Friedman A, Liao W-C, et al. Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 1999;59(20):5194-201 (Pubitemid 29503982)
25. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4(5):397-407 (Pubitemid 36565571)
26. Spiegel S, Milstien S. Functions of the multifaceted family of sphingosine kinases and some close relatives. J Biol Chem 2007;282(4):2125-9 (Pubitemid 47076736)
27. Bonnaud S, Niaudet C, Pottier G, et al. Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death. Cancer Res 2007;67(4):1803-11 (Pubitemid 46389242)
28. Chmura SJ, Nodzenski E, Kharbanda S, et al. Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol Pharmacol 2000;57(4):792-6 (Pubitemid 30183721)
29. Santana P, Pena LA, Haimovitz-Friedman A, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996;86(2):189-99 (Pubitemid 26286102)
30. Litvak DA, Bilchik AJ, Cabot MC. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy. J Gastrointest Surg 2003;7(1):140-8; discussion 8 (Pubitemid 36875811)
31. Alphonse G, Bionda C, Aloy MT, et al. Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene 2004;23(15):2703-15 (Pubitemid 38586324)
32. Samsel L, Zaidel G, Drumgoole HM, et al. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 2004;58(4):382-93 (Pubitemid 38295032)
33. Chalfant CE, Rathman K, Pinkerman RL, et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 2002;277(15):12587-95 (Pubitemid 34952617)
34. Dobrowsky RT, Hannun YA. Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem 1992;267(8):5048-51
35. Chalfant CE, Kishikawa K, Mumby MC, et al. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem 1999;274(29):20313-7
36. Xin M, Deng X. Protein phosphatase 2A enhances the proapoptotic function of bax through dephosphorylation. J Biol Chem 2006;281(27):18859-67 (Pubitemid 44035545)
37. Lin SS, Bassik MC, Suh H, et al. PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem 2006;281(32):23003-12
38. Pastorino JG, Tafani M, Rothman RJ, et al. Functional consequences of the sustained or transient activation by bax of the mitochondrial permeability transition pore. J Biol Chem 1999;274(44):31734-9
39. Verheij M, van Blitterswijk WJ, Bartelink H. Radiation-induced apoptosis-the ceramide-SAPK signaling pathway and clinical aspects. Acta Oncol 1998;37(6):575-81 (Pubitemid 28557218)
40. Gulbins E. Regulation of death receptor signaling and apoptosis by ceramide. Pharmacol Res 2003;47(5):393-9 (Pubitemid 36379201)
41. Verheij M, Bose R, Lin XH, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996;380(6569):75-9 (Pubitemid 26076240)
42. Yao B, Zhang Y, Delikat S, et al. Phosphorylation of raf by ceramide-activated protein kinase. Nature 1995;378(6554):307-10
43. Kashiwagi K, Shirai Y, Kuriyama M, et al. Importance of C1B domain for lipid messenger-induced targeting of protein kinase C. J Biol Chem 2002;277(20):18037-45 (Pubitemid 34967616)
44. Deiss LP, Galinka H, Berissi H, et al. Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. EMBO J 1996;15(15):3861-70 (Pubitemid 26289796)
45. Pattingre S, Bauvy C, Carpentier S, et al. Role of JNK1-dependent Bcl-2 phosphorylation in ceramide-induced macroautophagy. J Biol Chem 2009;284(5):2719-28
46. Daido S, Kanzawa T, Yamamoto A, et al. Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res 2004;64(12):4286-93 (Pubitemid 38802435)
47. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004;206(2):169-80 (Pubitemid 38317287)
48. Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry 2001;40(16):4893-903 (Pubitemid 32332534)
49. Koch J, Gartner S, Li CM, et al. Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification of the first molecular lesion causing farber disease. J Biol Chem 1996;271(51):33110-5
50. Mao C, Xu R, Szulc ZM, et al. Cloning and characterization of a novel human alkaline ceramidase. A mammalian enzyme that hydrolyzes phytoceramide. J of Biol Chem 2001;276(28):26577-88
51. El Bawab S, Cungui M, Obeid LM, Hannun YA. Ceramidases in the regulation of ceramide levels and function. In: Quinn PJ, Kagan VE, editors, Subcellular biochemistry: phospholipid metabolism in apoptosis. New York: Kluwer Academic/Plenum Publishers; 2002. p. 187-205
52. Mao C, Obeid LM. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta (BBA) Mol Cell Biol Lipids 2008;1781(9):424-34
53. Li CM, Park JH, He XX, et al. The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression. Genomics 1999;62(2):223-31
54. Park J-H, Schuchman EH. Acid ceramidase and human disease. Biochim Biophys Acta (BBA) Biomembr 2006;1758(12):2133-8 (Pubitemid 44879370)
55. Hannun YA, Bell RM. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation [comment]. Science 1989;243(4890):500-7 (Pubitemid 19048748)
56. Spiegel S, Cuvillier O, Edsall LC, et al. Sphingosine-1-phosphate in cell growth and cell death. Ann NY Acad Sci 1998;845:11-8 (Pubitemid 28365296)
57. Spiegel S, Merrill AH. Sphingolipid metabolism and cell growth regulation. FASEB J 1996;10(12):1388-97 (Pubitemid 26347873)
58. Seelan RS, Qian C, Yokomizo A, et al. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 2000;29(2):137-46
59. Narla G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001;294(5551):2563-6 (Pubitemid 34027299)
60. Chen C, Hyytinen E-R, Sun X, et al. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 2003;162(4):1349-54 (Pubitemid 36350678)
61. Ito G, Uchiyama M, Kondo M, et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 2004;64(11):3838-43 (Pubitemid 38697293)
62. Kremer-Tal S, Reeves HL, Narla G, et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 2004;40(5):1047-52 (Pubitemid 39425559)
63. Reeves HL, Narla G, Ogunbiyi O, et al. Kruppel-Like Factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gasteroenterology 2004;126:1090-103 (Pubitemid 38451180)
64. Wang S, Chen S, Zhang W, Qiu F. KLF6mRNA expression in primary hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci 2004;24:585-7 (Pubitemid 41564193)
65. Yung-Ming Jeng H-CH. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 2003;105(5):625-9
66. Narla G, DiFeo A, Yao S, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005;65(13):5761-8 (Pubitemid 40911179)
67. Seppala EH, Autio V, Duggal P, et al. KLF6 IVS1-27G>A variant and the risk of prostate cancer in Finland. Eur Urol 2007;52(4):1076-81 (Pubitemid 47332015)
68. Park J-H, Eliyahu E, Narla G, et al. KLF6 is one transcription factor involved in regulating acid ceramidase gene expression. Biochim Biophys Acta (BBA) Gene Struct Expr 2005;1732(1-3):82-7 (Pubitemid 43267308)
69. Lucki N, Sewer MB. The cAMP responsive element binding protein (CREB) regulates the expression of acid ceramidase (ASAH1) in H295R human adrenocortical cells. Biochim Biophys Acta 2009;1791(8):706-13
70. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001;20(3-4):173-93
71. Gandellini P, Folini M, Zaffaroni N. Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol Med 2009;15(9):381-90
72. Saad AF, Meacham WD, Bai A, et al. The functional effects of acid ceramidase over-expression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 2007;6(9):1455-60 (Pubitemid 351590358)
73. Bedia C, Canals D, Matabosch X, et al. Cytotoxicity and acid ceramidase inhibitory activity of 2-substituted aminoethanol amides. Chem Physics Lipids 2008;156(1-2):33-40
74. Karahatay S, Thomas K, Koybasi S, et al. Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C18-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett 2007;256(1):101-11 (Pubitemid 47333333)
75. Bielawska A, Bielawski J, Szulc ZM, et al. Novel analogs of D-e-MAPP and B13. Part 2: Signature effects on bioactive sphingolipids. Bioorg Med Chem 2008;16(2):1032-45 (Pubitemid 351163040)
76. Szulc ZM, Mayroo N, Bai A, et al. Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents. Bioorg Med Chem 2008;16(2):1015-31 (Pubitemid 351163041)
77. Maceyka M, Alvarez SE, Milstien S, Spiegel S. Filamin A links sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. Mol Cell Biol 2008;28(18):5687-97
78. Shah MV, Zhang R, Irby R, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008;112(3):770-81
79. Musumarra G, Barresi V, Condorelli DF, Scirè S. A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics. Biol Chem 2003;384(2):321-7 (Pubitemid 36348334)
80. Elojeimy S, Liu X, McKillop JC, et al. Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther 2007;15(7):1259-63 (Pubitemid 46965321)
81. Holman D, Turner L, El-Zawahry A, et al. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2008;61(2):231-42 (Pubitemid 350160321)
82. Eto M, Bennouna J, Hunter OC, et al. C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. Prostate 2003;57(1):66-79 (Pubitemid 37070151)
83. Eto M, Bennouna J, Hunter OC, et al. Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells. Int J Urol 2006 02;13(2):148-56 (Pubitemid 43362971)
84. Strelow A, Bernardo K, Adam-Klages S, et al. Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med 2000;192(5):601-12
85. Morales A, Paris R, Villanueva A, et al. Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene 2006;26(6):905-16
86. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12 (Pubitemid 39315317)
87. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20 (Pubitemid 39315318)
88. Kumar P, Perrotti M, Weiss R, et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol 2004;22(10):1909-15 (Pubitemid 41095183)
89. Sanfilippo NJ, Taneja SS, Chachoua A, et al. Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J Clin Oncol 2008;26(18):2973-8
90. Sui M, Dziadyk JM, Zhu X, Fan W. Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy. Clin Cancer Res 2004;10(14):4848-57 (Pubitemid 38955539)
91. Liebmann J, Cook JA, Fisher J, et al. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (taxol). Int J Radiat Oncol Biol Phys 1994;29(3):559-64 (Pubitemid 24187928)
92. Ingram ML, Redpath JL Subadditive interaction of radiation taxol in vitro. Int J Radiat Oncol Biol Phys 1997;37(5):1139-44 (Pubitemid 27230040)
93. Stromberg JS, Lee YJ, Armour EP, et al. Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer 1995;75(9):2262-8
94. Geard CR, Jones JM. Radiation and taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 1994;29(3):565-9 (Pubitemid 24187929)
95. Mehta S, Blackinton D, Omar I, et al. Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line. Cancer Chemother Pharmacol 2000;46(2):85-92 (Pubitemid 30624840)
96. Selzner M, Bielawska A, Morse MA, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001;61(3):1233-40 (Pubitemid 32174448)
97. Saddoughi SA, Song P, Ogretmen B Roles of bioactive sphingolipids in cancer biology therapeutics. Subcell. Biochem 2008;49:413-40
98. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism-a strategy for overcoming drug resistance. J Natl Cancer Inst 2001;93(5):347-57 (Pubitemid 32229379)
99. Raisova M, Goltz G, Bektas M, et al. Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett 2002;516(1-3):47-52 (Pubitemid 34311931)
100. Bai A, Szulc ZM, Bielawski J, et al. Synthesis and bioevaluation of w-N-amino analogs of B13. Bioorg Med Chem 2009;17(5):1840-8